Cancer Immunotherapy.

Cancer Cancer vaccine Canine Feline Immunotherapy Monoclonal antibody

Journal

The Veterinary clinics of North America. Small animal practice

ISSN: 1878-1306

Titre abrégé: Vet Clin North Am Small Anim Pract

Pays: United States

ID NLM: 7809942

Informations de publication

Date de publication:
28 Dec 2023

Historique:

medline: 2 1 2024

pubmed: 2 1 2024

entrez: 29 12 2023

Statut: aheadofprint

Résumé

The enhanced understanding of immunology experienced over the last 5 decades afforded through the tools of molecular biology has recently translated into cancer immunotherapy becoming one of the most exciting and rapidly expanding fields. Human cancer immunotherapy is now recognized as one of the pillars of treatment alongside surgery, radiation, and chemotherapy. The field of veterinary cancer immunotherapy has also rapidly advanced in the last decade with a handful of commercially available products and a plethora of investigational cancer immunotherapies, which will hopefully expand our veterinary oncology treatment toolkit over time.

Identifiants

DOI: 10.1016/j.cvsm.2023.12.002 PMID: 38158304

pubmed: 38158304

pii: S0195-5616(23)00170-5

doi: 10.1016/j.cvsm.2023.12.002

pii:

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Déclaration de conflit d'intérêts

Disclosure Dr P.J. Bergman is a co-inventor on patent US7556805B2 and was the veterinary principal investigator for the canine melanoma vaccine Oncept which received USDA-CVB conditional licensure in 2007 and full licensure in December of 2009. He also receives a minority royalty stream payment.